ReviewFrontiers in immunology2020
Adaptive Immunity in Pulmonary Sarcoidosis and Chronic Beryllium Disease.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Bioinformatics analysis identifies candidate biomarkers associated with sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Article
- Immune responses in pulmonary sarcoidosis following COVID-19.Frontiers in immunology · 2025Article
- Infectious and non-infectious precipitants of sarcoidosis.Journal of autoimmunity · 2024Review
- Sarcoidosis: a general overview.Advances in rheumatology (London, England) · 2024Review
- Bilateral Dacryoadenitis As the First Presentation in an Undiagnosed Sarcoidosis Patient.Cureus · 2023Article
- Immunoprofiling bronchoalveolar lavage cells reveals multifaceted smoking-associated immune dysfunction.ERJ open research · 2023Article
- [The lungs: starting point for many diseases].Innere Medizin (Heidelberg, Germany) · 2023Review
- Protective role of tissue-resident Tregs in a murine model of beryllium-induced disease.JCI insight · 2022Article
- Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- BATF2 and PDK4 as diagnostic molecular markers of sarcoidosis and their relationship with immune infiltration.Annals of translational medicine · 2022Article
- Systemic immune response to vimentin and granuloma formation in a model of pulmonary sarcoidosis.Journal of translational autoimmunity · 2022Article
- T-Follicular Helper-like Cells in Sarcoidosis: Lending a Helping Hand.American journal of respiratory and critical care medicine · 2021Article
- Follicular Helper-like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis.American journal of respiratory and critical care medicine · 2021Article
- Article
- Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update.European journal of clinical investigation · 2021Review
- Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases.The Journal of clinical investigation · 2021Article
- Current concepts in granulomatous immune responses.Biologia futura · 2021Review
- Involvement of Dendritic Cells and Th17 Cells in Induced Tertiary Lymphoid Structures in a Chronic Beryllium Disease Mouse Model.Mediators of inflammation · 2021Article
- Inflammatory Pathways in Sarcoidosis.Advances in experimental medicine and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Pulmonary sarcoidosis and chronic beryllium disease (CBD) are inflammatory granulomatous lung diseases defined by the presence of non-caseating granulomas in the lung. CBD results from beryllium exposure in the workplace, while the cause of sarcoidosis remains unknown. CBD and sarcoidosis are both immune-mediated diseases that involve Th1-polarized inflammation in the lung. Beryllium exposure induces trafficking of dendritic cells to the lung in a mechanism dependent on MyD88 and IL-1α. B cells are also recruited to the lung in a MyD88 dependent manner after beryllium exposure in order to protect the lung from beryllium-induced injury. Similar to most immune-mediated diseases, disease susceptibility in CBD and sarcoidosis is driven by the expression of certain MHCII molecules, primarily
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.